KR880007521A - 항비루스성 화합물 - Google Patents

항비루스성 화합물 Download PDF

Info

Publication number
KR880007521A
KR880007521A KR870014274A KR870014274A KR880007521A KR 880007521 A KR880007521 A KR 880007521A KR 870014274 A KR870014274 A KR 870014274A KR 870014274 A KR870014274 A KR 870014274A KR 880007521 A KR880007521 A KR 880007521A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
group
hydroxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR870014274A
Other languages
English (en)
Korean (ko)
Inventor
제인 마틴 푸리포이 도로시
죠지 라힘 사드
Original Assignee
마이클 피터잭슨
더 웰컴 파운데이숀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이클 피터잭슨, 더 웰컴 파운데이숀 리미티드 filed Critical 마이클 피터잭슨
Publication of KR880007521A publication Critical patent/KR880007521A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Silicon Polymers (AREA)
KR870014274A 1986-12-15 1987-12-14 항비루스성 화합물 Ceased KR880007521A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds
GB8629892 1986-12-15

Publications (1)

Publication Number Publication Date
KR880007521A true KR880007521A (ko) 1988-08-27

Family

ID=10609013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870014274A Ceased KR880007521A (ko) 1986-12-15 1987-12-14 항비루스성 화합물

Country Status (30)

Country Link
US (1) US5079235A (enExample)
EP (3) EP0417560A1 (enExample)
JP (2) JPS63165397A (enExample)
KR (1) KR880007521A (enExample)
CN (2) CN87108265A (enExample)
AT (1) ATE88713T1 (enExample)
AU (2) AU601529B2 (enExample)
CA (1) CA1319143C (enExample)
CS (3) CS342591A3 (enExample)
DD (2) DD274766A5 (enExample)
DE (1) DE3785651T2 (enExample)
DK (2) DK654287A (enExample)
ES (1) ES2054693T3 (enExample)
FI (2) FI875487A7 (enExample)
GB (1) GB8629892D0 (enExample)
HU (4) HU200932B (enExample)
IE (2) IE930470L (enExample)
IL (3) IL95141A (enExample)
LT (1) LT2064B (enExample)
LV (1) LV5273A3 (enExample)
MC (1) MC1882A1 (enExample)
MX (1) MX9203216A (enExample)
NO (1) NO167576C (enExample)
NZ (1) NZ222898A (enExample)
PH (2) PH24104A (enExample)
PL (3) PL160321B1 (enExample)
PT (1) PT86356B (enExample)
RU (1) RU2036199C1 (enExample)
SU (1) SU1731064A3 (enExample)
ZA (1) ZA879382B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE113059T1 (de) * 1987-06-24 1994-11-15 Florey Howard Inst Nukleosid-derivate.
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
ES2111569T3 (es) * 1990-07-19 1998-03-16 Wellcome Found Inactivadores de enzimas.
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
CA2122365C (en) * 1991-11-26 2010-05-11 Brian Froehler Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
JP2823358B2 (ja) * 1992-05-26 1998-11-11 アルバータ リサーチ カウンスル 免疫抑制性および寛容原性修飾ルイス▲上ｃ▼およびＬａｃＮＡｃ化合物
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
AU674639B2 (en) * 1994-12-13 1997-01-02 Akira Matsuda 3'-substituted nucleoside derivatives
JPH11513992A (ja) * 1995-12-22 1999-11-30 イースト・カロライナ・ユニバーシティ シチジンデアミナーゼまたはデオキシシチジンデアミナーゼの過剰発現を伴う疾患を治療するための薬剤および方法
WO1997027849A1 (fr) * 1996-02-02 1997-08-07 Showa Shell Sekiyu K.K. Medicaments pour traiter les infections provoquees par le virus de l'herpes et compositions preventives pour empecher un retour de l'infection, contenant tous les deux des derives triterpeniques comme principe actif
RU2300381C2 (ru) * 1998-08-10 2007-06-10 Айденикс (Кайман) Лимитед β-L-2'-ДЕЗОКСИНУКЛЕОЗИДЫ ДЛЯ ЛЕЧЕНИЯ ГЕПАТИТА В
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
EP1569658A4 (en) * 2001-12-20 2007-05-30 Pharmassett Ltd TREATMENT OF EBV AND KHSV INFECTION AND AN ASSOCIATED ABNORMAL CELL PROLIFERATION
KR20070098798A (ko) 2004-12-03 2007-10-05 애드헤렉스 테크놀로지스 인크. Ｄｐｄ 억제제를 5-ｆｕ 및 5-ｆｕ 전구약물과 조합한투여방법
PT2757091T (pt) 2008-04-01 2017-07-24 Biosearch Tech Inc Sondas de fluoróforo e supressor de fluorescência de ácido nucleico estabilizadas
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
JP2013508293A (ja) 2009-10-14 2013-03-07 アドヘレックス テクノロジーズ， インコーポレイテッド ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
ES2764226T3 (es) * 2014-03-30 2020-06-02 Cepheid Oligómeros polinucleotídicos de citosina modificados y métodos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Also Published As

Publication number Publication date
CS275398B2 (en) 1992-02-19
EP0486477A2 (en) 1992-05-20
PL277927A1 (en) 1989-08-21
FI941523A7 (fi) 1994-03-31
MX9203216A (es) 1992-07-01
CS342591A3 (en) 1992-04-15
CA1319143C (en) 1993-06-15
CN87108265A (zh) 1988-07-13
US5079235A (en) 1992-01-07
PL269462A1 (en) 1989-06-26
PT86356B (pt) 1990-11-07
NO167576B (no) 1991-08-12
DD264924A5 (de) 1989-02-15
JPH03141292A (ja) 1991-06-17
LV5273A3 (lv) 1993-10-10
IE930470L (en) 1988-06-15
ES2054693T3 (es) 1994-08-16
PL160321B1 (pl) 1993-02-26
PL277926A1 (en) 1989-08-21
GB8629892D0 (en) 1987-01-28
FI941523L (fi) 1994-03-31
PH24104A (en) 1990-03-05
HU207735B (en) 1993-05-28
EP0486477A3 (en) 1992-06-17
EP0272065A3 (en) 1988-11-17
EP0417560A1 (en) 1991-03-20
DK654287D0 (da) 1987-12-14
FI875487A0 (fi) 1987-12-14
NO875209L (no) 1988-06-16
NO167576C (no) 1991-11-20
DK168323B1 (da) 1994-03-14
HU903829D0 (en) 1990-11-28
CS275402B6 (en) 1992-02-19
CS767588A3 (en) 1991-02-12
PH24870A (en) 1990-12-26
JPS63165397A (ja) 1988-07-08
PL160322B1 (pl) 1993-02-26
DE3785651T2 (de) 1993-11-11
EP0272065A2 (en) 1988-06-22
IL84810A0 (en) 1988-06-30
AU626041B2 (en) 1992-07-23
RU2036199C1 (ru) 1995-05-27
ATE88713T1 (de) 1993-05-15
DE3785651D1 (de) 1993-06-03
DD274766A5 (de) 1990-01-03
LT2064B (lt) 1993-06-15
NO875209D0 (no) 1987-12-14
NZ222898A (en) 1990-12-21
CN1080292A (zh) 1994-01-05
DK169991A (da) 1991-10-04
HUT46336A (en) 1988-10-28
IE930471L (en) 1988-06-15
HU202112B (en) 1991-02-28
HU200932B (en) 1990-09-28
EP0272065B1 (en) 1993-04-28
MC1882A1 (fr) 1989-01-24
AU5989090A (en) 1990-11-08
HU199867B (en) 1990-03-28
PT86356A (en) 1988-01-01
PL158050B1 (pl) 1992-07-31
DK169991D0 (da) 1991-10-04
DK654287A (da) 1988-06-16
IL95141A (en) 1992-05-25
IL84810A (en) 1992-05-25
CS916187A2 (en) 1991-02-12
ZA879382B (en) 1989-08-30
AU601529B2 (en) 1990-09-13
JPH0378370B2 (enExample) 1991-12-13
IL95141A0 (en) 1991-06-10
AU8252187A (en) 1988-06-16
FI941523A0 (fi) 1994-03-31
SU1731064A3 (ru) 1992-04-30
FI875487A7 (fi) 1988-06-16

Similar Documents

Publication Publication Date Title
KR880007521A (ko) 항비루스성 화합물
HUT61989A (en) Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient
EP0371731A3 (en) Quinazolinone derivatives
IL101203A0 (en) Cyclic urea derivatives,their preparation and pharmaceutical compositions containing them
KR890003761A (ko) 치료학적 아시클릭 뉴클레오시드
KR890003731A (ko) 인돌 유도체
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
FI832355A0 (fi) 9-(2-hydroxyetoximetyl)guanidin-derivat
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
KR910018398A (ko) 3당류 유니트(unit)를 함유하는 탄수화물 유도체
NO154089C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
ATE164848T1 (de) 4''-deoxyerythromycinderivate
TNSN90021A1 (fr) Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
TNSN89039A1 (fr) Tetrahydroimidazo(1,4)benzodiazepin-2-ones antivirales
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물
KR880007080A (ko) 제약학적 생성물
US5028595A (en) Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus
KR890008160A (ko) 약학적 뉴클레오시드
KR900011468A (ko) 치료용 뉴클레오시드
SE8007171L (sv) Forfarande for framstellning av en farmaceutisk komposition omfattande substituerade difenylsulfider
IL65787A0 (en) Antiviral pharmaceutical compositions containing alpha,alpha-dialkyl-adamantylamines
KR900012925A (ko) 인돌 유도체
KR970704723A (ko) 항염증제로서 유용한 디히드로벤조푸란 및 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19871214

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19920623

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19871214

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950724

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19951023

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19950724

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I